Recent advances in primary cutaneous T-cell lymphoma
Authors:
- Pooja SodhaPSPooja Sodha
- Desislava IgnatovaDIDesislava Ignatova
- Reinhard DummerRDReinhard Dummer
- Antonio CozzioACAntonio Cozzio
- Emmanuella GuenovaEmmanuella Guenova
- 1 March 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 27 (2) , 128-133
Abstract
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of skin-homing T-cell neoplasms, which represent approximately 75% of all primary cutaneous lymphomas. Currently available drug therapies, when effective, simply control disease and the only option for curing CTCL is stem cell transplant. In the last year, there has been an incredible effort made to improve the understanding and treatment of CTCL. Recent findings indicate that epigenetic aberrations are integral to active disease. Furthermore, multiple tumor-derived immunological factors have also been shown to inhibit viability, proliferation, and cytokine production of nonmalignant T cells. Several novel targeted therapies show great potential, most promising being antibody drug conjugates targeting surface markers such as CD30 in some CTCL subtypes. Additional attractive targets involve the global modulation of epigenetic markers such as demethylation agents or HDAC inhibitors, either as single agents or in combination therapies. This is a concise review of recent advances in the field of CTCL with special focus on research articles over the preceding year.Keywords
This publication has 52 references indexed in Scilit:
- Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00British Journal of Dermatology, 2012
- MogamulizumabDrugs, 2012
- Deep-Sequencing Analysis Reveals that the miR-199a2/214 Cluster within DNM3os Represents the Vast Majority of Aberrantly Expressed MicroRNAs in Sézary SyndromeJournal of Investigative Dermatology, 2012
- Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphomaBlood, 2012
- Autocrine IL-21 Stimulation Is Involved in the Maintenance of Constitutive STAT3 Activation in Sézary SyndromeJournal of Investigative Dermatology, 2012
- miRNA expression profiling of mycosis fungoidesMolecular Oncology, 2011
- Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2010
- IL‐4‐mediated fine tuning of IL‐12p70 production by human DCEuropean Journal of Immunology, 2008
- Epigenetic Profiling of Cutaneous T-Cell Lymphoma: Promoter Hypermethylation of Multiple Tumor Suppressor Genes Including BCL7a, PTPRG, and p73Journal of Clinical Oncology, 2005
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005